ArticleBMJ case reports2009
Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages.
Article in BMJ case reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 44 citations in OpenAlex.
- Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy.JCEM case reports · 2025Article
- Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment.Endocrine · 2021Article
- Medical transition for gender diverse patients.Current obstetrics and gynecology reports · 2020Article
- Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review.International journal of transgender health · 2020Review
- Endocrine treatment of aging transgender people.Reviews in endocrine & metabolic disorders · 2018Review
- Article
- Cancer in Transgender People: Evidence and Methodological Considerations.Epidemiologic reviews · 2017Review
- Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals.Journal of clinical & translational endocrinology · 2015Article
- Galactorrhea and Pituitary Microadenoma in an 18-Year-Old Transfeminine Youth: A Case Report.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oestrogen-induced prolactinomas have been reported in male-to-female (MTF) transgender patients after excessive oestrogen self-administration. Here, two prolactinoma cases after 14 years (case 1) and 30 years (case 2) of relatively low-dose oestrogen treatment are reported. Both resolved after treatment with dopamine agonists. During the first year of oestrogen treatment the patient in case 1 showed a remarkable (7.2-fold) increase in serum prolactin concentration, returning to within the normal range for 13 years until the start of autonomous prolactin secretion. It is hypothesised that this strong first-year prolactin response may be a sign of increased pituitary oestrogen sensitivity. Therefore the patient's increase in prolactin concentration during the first 18 months was compared to 74 matched control patients from a database, and this increase was found to be significantly greater in the case patient. It is suggested that in MTF patients an excessive first year increase in serum prolactin concentration may identify patients at risk for autonomous prolactin secretion later in life.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.